LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

Начало・Списък с акции・AbbVie Inc

AbbVie Inc

Затворен

СекторЗдравеопазване

202.82 0.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

201.14

Максимум

205.19

Ключови измерители
By Trading Economics
Приходи	1.6B 1.8B
Продажби	-1.6B 15B
P/E Средно за сектора	101.049 49.8
EPS	2.65
Дивидентна доходност	3.26
Марж на печалбата	10.928
Служители	57,000
EBITDA	-635M 4.7B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+25.99% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	3.26% 2.25%
Следващи печалби	30.07.2026 г.
Следваща дата на дивидент	15.05.2026 г.
Следваща дата на екс-дивидент	14.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	19B 368B
Предишно отваряне	201.98
Предишно затваряне	202.82

Настроения в новините

By Acuity

29%

71%

98 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

180.37 / 195.54 Подкрепа & съпротива

AbbVie Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.04.2026 г., 12:38 ч. UTC

Печалби

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4.02.2026 г., 13:20 ч. UTC

Печалби

AbbVie 4Q Revenue Rises on Immunology Growth

29.04.2026 г., 12:41 ч. UTC

Печалби

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29.04.2026 г., 12:23 ч. UTC

Печалби

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29.04.2026 г., 11:50 ч. UTC

Печалби

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29.04.2026 г., 11:49 ч. UTC

Печалби

AbbVie 1Q Global Humira Rev $688 M >ABBV

29.04.2026 г., 11:48 ч. UTC

Печалби

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q EPS 39c >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q Net $695M >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q Rev $15B >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q Adj EPS $2.65 >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29.04.2026 г., 11:47 ч. UTC

Печалби

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4.02.2026 г., 19:38 ч. UTC

Печалби

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4.02.2026 г., 16:19 ч. UTC

Печалби

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4.02.2026 г., 15:18 ч. UTC

Печалби

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4.02.2026 г., 13:18 ч. UTC

Печалби

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie 4Q Rev $16.62B >ABBV

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie 4Q Net $1.82B >ABBV

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie 4Q Adj EPS $2.71 >ABBV

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4.02.2026 г., 12:48 ч. UTC

Печалби

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Сравнение с други в отрасъла

Ценова промяна

AbbVie Inc Прогноза

Ценова цел

By TipRanks

25.99% нагоре

12-месечна прогноза

Среден 253.94 USD 25.99%

Висок 294 USD

Нисък 203 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за AbbVie Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на AbbVie Inc през последните 3 месеца.

Техническа оценка

By Trading Central

180.37 / 195.54Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

98 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.